Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

A. Venneri; M. F. Shanks; Roger T Staff; S. J. Pestell; K. E. Forbes; Howard .g. Gemmell; Alison Dorothy Murray

doi:10.1097/00001756-200201210-00020

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

A. Venneri, M. F. Shanks, Roger T Staff, S. J. Pestell, K. E. Forbes, Howard .g. Gemmell, Alison Dorothy Murray

Research output: Contribution to journal › Article › peer-review

107 Citations (Scopus)

Abstract

Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.

Original language	English
Pages (from-to)	83-87
Number of pages	4
Journal	Neuroreport
Volume	13
Issue number	1
DOIs	https://doi.org/10.1097/00001756-200201210-00020
Publication status	Published - 21 Jan 2002

Keywords

TOMOGRAPHY
PHYSOSTIGMINE
DIAGNOSIS
THERAPY
BRAIN

Access to Document

10.1097/00001756-200201210-00020Licence: Unspecified

Cite this

@article{3ed8b4c40268443da2c249fbc6143a60,

title = "Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease",

abstract = "Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.",

keywords = "TOMOGRAPHY, PHYSOSTIGMINE, DIAGNOSIS, THERAPY, BRAIN",

author = "A. Venneri and Shanks, {M. F.} and Staff, {Roger T} and Pestell, {S. J.} and Forbes, {K. E.} and Gemmell, {Howard .g.} and Murray, {Alison Dorothy}",

year = "2002",

month = jan,

day = "21",

doi = "10.1097/00001756-200201210-00020",

language = "English",

volume = "13",

pages = "83--87",

journal = "Neuroreport",

issn = "0959-4965",

publisher = "LWW",

number = "1",

}

TY - JOUR

T1 - Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

AU - Venneri, A.

AU - Shanks, M. F.

AU - Staff, Roger T

AU - Pestell, S. J.

AU - Forbes, K. E.

AU - Gemmell, Howard .g.

AU - Murray, Alison Dorothy

PY - 2002/1/21

Y1 - 2002/1/21

N2 - Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.

AB - Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.

KW - TOMOGRAPHY

KW - PHYSOSTIGMINE

KW - DIAGNOSIS

KW - THERAPY

KW - BRAIN

U2 - 10.1097/00001756-200201210-00020

DO - 10.1097/00001756-200201210-00020

M3 - Article

SN - 0959-4965

VL - 13

SP - 83

EP - 87

JO - Neuroreport

JF - Neuroreport

IS - 1

ER -

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this